ALS Association
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Evotec appoints Ingrid Müller as Chief Operating Officer
Most recently, Müller held senior international leadership roles at CureVac, Sanofi and Fresenius Kabi
Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities
Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity
Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease
Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease
Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m
The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease
Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies
The neurodegenerative disease affects approximately 30,000 people in the US
Innovate UK awards Sano Genetics £330,000 grant for ALS study
The project will chart the psychological impacts of having a genetic predisposition to ALS
Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS
Mutations in the SOD1 gene are responsible for approximately 2% of all cases
Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure
The neurodegenerative disease affects approximately 27,000 people in the US
Biogen’s tofersen shows promise in rare form of ALS in new data analysis
Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022.
Almirall and Evotec team up in multi-target dermatology alliance
The companies will focus on developing novel therapies for chronic skin diseases and skin cancer